CHICAGO — In this video from ASCO Annual Meeting, Andrew J. Armstrong, MD, MS, discusses final results of the phase 2 CHAMP trial evaluating a chemoimmunotherapy regimen in neuroendocrine or aggressive-variant metastatic prostate cancer.
The primary endpoint was progression-free survival after a chemoimmunotherapy regimen.
“This was an effective regimen, and it’s something that now should be studied in randomized, controlled trials to see if we can improve survival,” Armstrong, medical oncologist and professor at Duke Cancer Institute, told Healio. “This is really a major unmet need, accounting

CHICAGO — In this video, Erika P. Hamilton, MD, discusses results from the HER2CLIMB-05 trial of tucatinib in combination with trastuzumab and pertuzumab as first-line maintenance therapy in HER2-positive metastatic breast cancer.
The study, which compared tucatinib (Tukysa; Pfizer, Seagen) vs. placebo in combination with trastuzumab (Herceptin, Genentech) and pertuzumab (Perjeta, Genentech), was presented at ASCO Annual Meeting.
Results demonstrated that tucatinib extended progression-free survival without new safety signals for women with HER2-positive metastatic breast cancer.
“Regardless of